Merck Names Sanat Chattopadhyay President of Merck Manufacturing Division; Will Succeed Willie A. Deese Who Will Retire

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the appointment of Sanat Chattopadhyay as executive vice president and president, Merck Manufacturing Division (MMD), effective April 1, 2016. Chattopadhyay will succeed Willie A. Deese who will retire on June 1, 2016 after 12 years with the company.

"With more than 30 years of biopharmaceutical industry experience, Sanat has a proven track record of commercialization, manufacturing and supply chain excellence in therapeutic proteins, vaccines and pharmaceuticals. Under his leadership I am confident that MMD will continue to advance toward its goal of becoming a world-class supplier"
"With more than 30 years of biopharmaceutical industry experience, Sanat has a proven track record of commercialization, manufacturing and supply chain excellence in therapeutic proteins, vaccines and pharmaceuticals. Under his leadership I am confident that MMD will continue to advance toward its goal of becoming a world-class supplier," said Kenneth C. Frazier, chairman and chief executive officer, Merck.

Chattopadhyay joined Merck in 2009 and currently serves as senior vice president of Global Manufacturing Operations (Human Health). He was instrumental in transforming Merck Vaccines' manufacturing and supply to grow and globalize the company's vaccines business. Chattopadhyay also played a key part in leading the company's launch of KEYTRUDA (pembrolizumab) in record time by mobilizing a cross-divisional effort to overcome commercialization and supply constraints.

Deese joined Merck in 2004 to lead the global procurement team in MMD. In 2005, he was promoted to president of MMD and joined the company's executive committee. Among his many accomplishments as president of MMD was the "Target '15" strategy, a five-year program that improved both operational efficiencies in manufacturing and financial results. Additionally, Deese led the company's multi-year, strategic initiative to sharpen its commercial and research and development focus, redesign its operating model and reduce its cost base. The initiative succeeded in exceeding its goal by the end of 2015 of realizing $2.5 billion in annual net cost savings versus 2012.

"Under Willie's leadership, we significantly improved our ability to serve patients and customers globally and transformed our operating model," said Frazier. "I would like to thank Willie for his unwavering focus on high performance, safety, compliance, and above all, customers and patients."

About Merck

Today's Merck is a global health care leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook, YouTube and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's 2015 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

Contacts

Merck
Media:
Lainie Keller, 908-236-5036
or
Claire Gillespie, 267-305-0932
or
Investor:
Teri Loxam, 908-740-1986
or
Justin Holko, 908-740-1879
 

Read more on